Christopher Azzoli is an Oncology physician affiliated with Rhode Island Hospital. OpenAlex indexes 267 publications with 14,992 citations (h-index 55); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100216007
Telephone
646-227-3813Registry record last updated 11 Jul 2013.
Clinical trials
- Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Sponsor: Memorial Sloan Kettering Cancer Center
- Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Medtronic, Inc.Program year20252 payments
- Janssen Biotech, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
27.6%Proton pump inhibitor9.2%Omeprazole100%Part D≥21 patientsCorticosteroid6.4%Prednisone100%Part D≥26 patients+ 3 more classes in this area
Nervous system
24.9%Phenothiazine11.3%Prochlorperazine Maleate100%Part D≥56 patientsOpioid Agonist10.1%Oxycodone Hcl79%Oxycodone-Acetaminophen21%Part D<11 patients+ 1 more class in this area
Sensory organs
13.6%Corticosteroid13.6%Dexamethasone82%Hydrocortisone19%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2012–2012 per NIH RePORTER. The latest:
- Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT
Sloan-Kettering Inst Can Research
FY2012$630,024U01CA157442
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Nature Reviews Clinical Oncology
2021 - MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Clinical Cancer Research
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Khaldoun Almhanna, MD, MPH
Rhode Island Hospital
Albert Most, MD
Rhode Island Hospital
Amanda Pressman, MD
Rhode Island Hospital
Ali Naboush, MD
Rhode Island Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”